David Pickar

List of Publications by Year
in descending order

117 papers	8,410 citations	44069 48 h-index	46799 89 g-index
117 all docs	117 docs citations	117 times ranked	4567 citing authors

#	Article	IF	Citations
1	Pharmacogenomics of psychiatric drug treatment. Psychiatric Clinics of North America, 2003, 26, 303-321.	1.3	11
2	Effect Size of Symptom Status in Withdrawal of Typical Antipsychotics and Subsequent Clozapine Treatment in Patients With Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2003, 160, 1133-1138.	7.2	20
3	Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia. Neuropsychopharmacology, 2002, 26, 295-300.	5.4	11
4	Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. Neuropsychopharmacology, 2002, 27, 293-300.	5.4	24
5	Pharmacogenomics of psychiatric disorders. Trends in Pharmacological Sciences, 2001, 22, 75-83.	8.7	68
6	Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia. American Journal of Psychiatry, 1999, 156, 1646-1649.	7.2	313
7	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology, 1999, 20, 29-34.	5.4	56
8	Effects of Atypical Antipsychotic Drug Treatment on Amphetamine-Induced Striatal Dopamine Release in Patients with Psychotic Disorders. Neuropsychopharmacology, 1999, 20, 340-345.	5.4	17
9	The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia Evidence of a Sex Effect. Neuropsychopharmacology, 1999, 21, 632-640.	5.4	23
10	Predicting Response to Clozapine. CNS Drugs, 1999, 11, 317-326.	5.9	11
11	Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia. Neuropsychopharmacology, 1998, 19, 36-47.	5.4	38
12	The Apolipoprotein E Îµ4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia A Preliminary Report. Neuropsychopharmacology, 1998, 19, 445-448.	5.4	17
13	Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. , 1998, 29, 142-147.		175
14	Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers. Biological Psychiatry, 1998, 43, 811-816.	1.3	278
15	Challenges in patient management. European Psychiatry, 1998, 13, 219s-219s.	0.2	0
16	Cognitive Substrates of Thought Disorder, I: The Semantic System. American Journal of Psychiatry, 1998, 155, 1671-1676.	7.2	276
17	Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia. American Journal of Psychiatry, 1998, 155, 979-981.	7.2	72
18	Dopamine D₂Receptor Density and Personal Detachment in Healthy Subjects. American Journal of Psychiatry, 1998, 155, 1440-1442.	7.2	117

#	Article	IF	Citations
19	Cognitive Substrates of Thought Disorder, II: Specifying a Candidate Cognitive Mechanism. American Journal of Psychiatry, 1998, 155, 1677-1684.	7.2	116
20	CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophrenia Research, 1997, 25, 123-129.	2.0	53
21	Apolipoprotein E Îµ4 and clinical phenotype in schizophrenia. Lancet, The, 1997, 350, 930-931.	13.7	31
22	Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine. Biological Psychiatry, 1997, 42, 664-668.	1.3	185
23	Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 437-447.	4.3	237
24	Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics. Neuropsychopharmacology, 1997, 17, 141-150.	5.4	603
25	Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research, 1996, 22, 215-222.	2.0	35
26	Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia. British Journal of Psychiatry, 1996, 168, 571-579.	2.8	128
27	Clozapine response and the 5HT2C Cys23Ser polymorphism. NeuroReport, 1996, 7, 2100-2102.	1.2	78
28	Biologic Predictors of Clozapine Response in Schizophrenia. Psychiatric Annals, 1996, 26, 390-394.	0.1	4
29	Increased serum soluble interleukin-2 receptors in caucasian and Korean schizophrenic patients. Biological Psychiatry, 1994, 35, 767-771.	1.3	61
30	Spectrum of EEG abnormalities during clozapine treatment. Electroencephalography and Clinical Neurophysiology, 1994, 91, 205-211.	0.3	66
31	Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophrenia Research, 1994, 12, 107-120.	2.0	49
32	Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 1994, 13, 133-143.	2.0	57
33	Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. European Archives of Psychiatry and Clinical Neuroscience, 1993, 243, 7-10.	3.2	71
34	Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology, 1993, 112, S76-S84.	3.1	27
35	Adverse Effects of Antipsychotic Drugs. Drug Safety, 1993, 9, 429-436.	3.2	38
36	Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine. Biological Psychiatry, 1993, 34, 3-12.	1.3	72

#	Article	IF	Citations
37	Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients. Neuropsychopharmacology, 1993, 9, 111-115.	5.4	30
38	Idazoxan, an ??2 Antagonist, Augments Fluphenazine in. Journal of Clinical Psychopharmacology, 1993, 13, 264???267.	1.4	31
39	The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia. British Journal of Psychiatry, 1993, 162, 43-48.	2.8	283
40	Is the Mechanism of Prefrontal Hypofunction in Depression the Same as in Schizophrenia?. British Journal of Psychiatry, 1993, 162, 183-192.	2.8	119
41	Clinical and Biologic Response to Clozapine in Patients With Schizophrenia. Archives of General Psychiatry, 1992, 49, 345.	12.3	352
42	The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Life Sciences, 1991, 48, 1411-1416.	4.3	22
43	Maladaptive anticipatory saccades in schizophrenia. Biological Psychiatry, 1991, 30, 779-794.	1.3	55
44	Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia. Modern Problems of Pharmacopsychiatry, 1990, 24, 124-151.	2.5	16
45	Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis. Archives of General Psychiatry, 1990, 47, 641.	12.3	89
46	Drug trials and heterogeneity in schizophrenia: The mean is not the end. Biological Psychiatry, 1990, 28, 1021-1025.	1.3	13
47	Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Research, 1990, 33, 259-267.	3.3	7
48	Alprazolam-neuroleptic treatment in schizophrenia. Schizophrenia Research, 1989, 2, 215.	2.0	1
49	Specificity of plasma HVA response to dexamethasone in psychotic depression. Psychiatry Research, 1989, 29, 177-186.	3.3	17
50	Cerebral structure in borderline personality disorder. Psychiatry Research, 1989, 27, 111-115.	3.3	30
51	Suicidal behavior in depression: Relationship to noradrenergic function. Biological Psychiatry, 1989, 25, 341-350.	1.3	29
52	Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA. Biological Psychiatry, 1989, 25, 431-439.	1.3	25
53	Increased temporal lobe glucose use in chronic schizophrenic patients. Biological Psychiatry, 1989, 25, 835-851.	1.3	131
54	TRH-induced prolactin release in unipolar depressed patients and controls. Journal of Psychiatric Research, 1988, 22, 221-225.	3.1	3

#	Article	IF	Citations
55	Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients. Annals of the New York Academy of Sciences, 1988, 537, 339-346.	3.8	27
56	Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Research, 1988, 25, 187-194.	3.3	65
57	The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1988, 43, 1141-1150.	4.3	48
58	Single-dose naloxone acutely reduces eating in obese humans: Behavioral and biochemical effects. Biological Psychiatry, 1988, 24, 483-487.	1.3	28
59	A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid. Brain Research Bulletin, 1988, 20, 567-571.	3.0	10
60	Urinary-free cortisol in depressed patients and controls: relationship to urinary indices of noradrenergic function. Psychological Medicine, 1988, 18, 93-98.	4.5	18
61	Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients. Archives of General Psychiatry, 1987, 44, 113.	12.3	57
62	Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatry Research, 1987, 21, 161-168.	3.3	40
63	Cerebrospinal fluid corticotropin-releasing hormone in depression: Relationship to noradrenergic function. Psychiatry Research, 1987, 20, 229-237.	3.3	47
64	Prednisone decreases CSF somatostatin in healthy humans: Implications for neuropsychiatric illness. Life Sciences, 1987, 41, 1929-1933.	4.3	27
65	Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1987, 40, 2031-2039.	4.3	132
66	Chronic corticosterone administration in rats: Behavioral and biochemical evidence of increased central dopaminergic activity. European Journal of Pharmacology, 1986, 122, 329-338.	3.5	69
67	Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. Journal of Affective Disorders, 1986, 10, 95-99.	4.1	34
68	Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. Biological Psychiatry, 1986, 21, 366-373.	1.3	15
69	Urinary excretion of free tyramine and of norepinephrine and its metabolites in unipolar depressed patients. Biological Psychiatry, 1986, 21, 221-224.	1.3	9
70	Neurobiologic Correlates. Annals of the New York Academy of Sciences, 1986, 487, 189-196.	3.8	33
71	Responses to Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease. New England Journal of Medicine, 1986, 314, 1329-1335.	27.0	762
72	Symptoms and EEG Findings in the Borderline Syndrome. International Journal of Psychiatry in Medicine, 1986, 15, 201-211.	1.8	83

#	Article	IF	Citations
73	Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. Psychological Medicine, 1986, 16, 541-546.	4.5	50
74	Longitudinal Measurement of Plasma Homovanillic Acid Levels in Schizophrenic Patients. Archives of General Psychiatry, 1986, 43, 669.	12.3	310
75	Pre-Menopausal and Post-Menopausal Depressed Women. Australian and New Zealand Journal of Psychiatry, 1986, 20, 464-469.	2.3	6
76	Studies of the Endogenous Opioid System in the Human Stress Response. , 1986, , 35-45.		9
77	CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine, 1985, 15, 335-340.	4.5	68
78	Naloxone Reduces Food Intake in Humans. Psychosomatic Medicine, 1985, 47, 132-138.	2.0	47
79	Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology, 1985, 86, 432-437.	3.1	83
80	Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication. Journal of Cerebral Blood Flow and Metabolism, 1985, 5, 201-206.	4.3	175
81	Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. Pharmacology Biochemistry and Behavior, 1985, 23, 921-925.	2.9	14
82	Lithium Potentiation of Imipramine in Treatment Resistant Depression. British Journal of Psychiatry, 1985, 147, 582-583.	2.8	11
83	High-dose naloxone administration in chronic schizophrenia. Biological Psychiatry, 1985, 20, 573-575.	1.3	21
84	Life events in depression Relationship to subtypes. Journal of Affective Disorders, 1985, 9, 143-148.	4.1	44
85	Dexamethasone increases plasma HVA but not MHPG in normal humans. Psychiatry Research, 1985, 16, 101-109.	3.3	43
86	Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Research, 1985, 15, 281-292.	3.3	112
87	Hormonal effects of high dose naloxone in humans. Neuropeptides, 1985, 6, 373-380.	2.2	23
88	Biologic tests in depression. Psychosomatics, 1984, 25, 443-451.	2.5	28
89	Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping. Psychiatry Research, 1984, 12, 227-233.	3.3	50
90			

#	Article	IF	Citations
91	High-dose naloxone affects task performance in normal subjects. Psychiatry Research, 1983, 8, 127-136.	3.3	49
92	The relationship of plasma cortisol and Î²-endorphin immunoreactivity to surgical stress and postoperative analgesic requirement. General Hospital Psychiatry, 1983, 5, 93-98.	2.4	22
93	Extreme Elevations in Plasma Norepinephrine Associated with Decreased ??-Adrenergic Responsivity in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 1983, 3, 39???41.	1.4	12
94	The Role of the Endogenous Opioid System in the Human Stress Response. Psychiatric Clinics of North America, 1983, 6, 457-471.	1.3	39
95	Selective and Nonselective Monoamine Oxidase Inhibitors. Archives of General Psychiatry, 1982, 39, 535.	12.3	34
96	Effects of Fentanyl on the Response of Plasma Beta-Endorphin Immunoreactivity to Surgery. Anesthesiology, 1982, 57, 468-472.	2.5	38
97	Short-term Naloxone Administration in Schizophrenic and Manic Patients. Archives of General Psychiatry, 1982, 39, 313.	12.3	100
98	Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage. Psychiatry Research, 1982, 6, 7-12.	3.3	66
99	Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psychiatry Research, 1982, 7, 171-178.	3.3	9
100	Physiological effects of high dose naloxone administration to normal adults. Life Sciences, 1982, 30, 2025-2031.	4.3	59
101	Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. European Journal of Pharmacology, 1982, 80, 155-160.	3.5	14
102	ENDORPHINS IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS. Annals of the New York Academy of Sciences, 1982, 398, 399-412.	3.8	19
103	CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM. Annals of the New York Academy of Sciences, 1982, 398, 424-432.	3.8	6
104	Endorphins and Affective Illness. , 1982, , 375-397.		3
105	Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. Life Sciences, 1981, 28, 931-935.	4.3	60
106	Dextroamphetamine infusions in normals result in correlated increases of plasma Î²-endorphin and cortisol immunoreactivity. Life Sciences, 1981, 29, 1243-1247.	4.3	29
107	Surgical stress in humans is acompanied by an increase in plasma beta-endorphin immunoreactivity. Life Sciences, 1981, 29, 1249-1254.	4.3	132
108	Effect of carbamazepine on CSF opioid activity: Relationship to antidepressant response. Psychiatry Research, 1981, 5, 59-66.	3.3	12

#	Article	IF	Citations
109	Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Research, 1981, 5, 87-93.	3.3	19
110	BEHAVIOURAL EFFECTS AFTER HIGH DOSE NALOXONE ADMINISTRATION TO NORMAL VOLUNTEERS. Lancet, The, 1981, 318, 1110.	13.7	73
111	Measurement of Endorphins in CSF. Modern Problems of Pharmacopsychiatry, 1981, 17, 246-262.	2.5	8
112	Pharmacological Challenges to the Endogenous Opioid System in Affective Illness. Journal of Clinical Psychopharmacology, 1981, 1, 223-231.	1.4	10
113	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 4-7.	3.1	44
114	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 8-12.	3.1	30
115	Naloxone effects on ?-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology, 1981, 74, 125-128.	3.1	87
116	Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Research, 1980, 3, 93-105.	3.3	91
117	PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS. Lancet, The, 1980, 315, 937.	13.7	38